Vaxil Bio Ltd V.VXL

Alternate Symbol(s): VXLLF

Healthcare Biotechnology

Vaxil Bio Ltd. is a Canada-based biotechnology company. The Company is focused on a drug discovery and development platform based on Signal Peptides (SPs) which the Company deploys to fight infectious diseases and cancer. The Company’s most advanced product, ImMucin, a MUC1 SP-derived vaccine, completed a Phase I/II clinical trial in multiple myeloma. The Company also has a SP-based COVID-19 vaccine candidate and a SP-based tuberculosis vaccine / treatment candidate. In addition, The Company has mAb candidates for the treatment of oncology and infectious diseases to be used alone, and in combination with other treatments. It has also initiated a pre-clinical program for a drug delivery polymer that targets high affinity E-selectin (P-Esbp), which the Company licensed for development and commercialization from BGN Technologies. It exploits the properties of SP domains on crucial proteins to develop targeted therapies against cancer targets and infectious disease pathogens.

TSXV:VXL - Post by User

Vaxil Bio Ltd > Today's update was interesting, why

<< Previous

Bullboard Posts

Next >>

Comment by bigbanktheoryon Dec 03, 2020 4:25pm

73 Views

Post# 32030833

RE:RE:Today's update was interesting, why

90guppy wrote: Bingo, bigbank, looks like there are two targets now for VXL. The US govt and Israel, it seems the clinical trial is gonna move as well in Israel, including this oral route

bigbanktheory wrote: Why would Vxl even mention taking it orally if they know their results are negative?

Hey 90Guppy. I hope all is good. For me, the ace up the sleeve is the patent. If we get that soon, it could blend into the equation with perfect timing. But I have no idea. What are your thoughts?

<< Previous

Bullboard Posts

Next >>

Changing Europe’s dependency on HREE from China